Cinpanemab in Early Parkinson's Disease | NEJM

Parkinson's Disease - An Overview

240515 Trial of Cinpanemab in Early Parkinson’s Disease

Parkinson’s Disease: Current Status and Potential Role of Emerging Agents Targeting Alpha-Synuclein

IV Fluid Restriction in Septic Shock | NEJM

Parkinson's Disease Accommodation Without Surrender

Triplet Therapy, Transplantation, and Maintenance in Myeloma | NEJM

Adjunctive Tools to Guide PCI | NEJM

Parkinson’s Disease and it’s early symptoms

PCI for Ischemic Left Ventricular Dysfunction | NEJM

Parkinson’s Disease. Media showcase

Get to Know About Skin Punch Biopsy for Alpha Synuclein Protein at Sharlin Health and Neurology

Ep. 34 Parkinson’s Forever?

Assessing the efficacy of antibodies targeting α-synuclein

Next Generation Therapeutics for Parkinson’s Disease

parkinson disease - symptoms, causes and prevention

Dr. David Finkelstein with Linda Williams on Targeting Brain Iron in Multiple System Atrophy

Slower is Better: Progress Towards Neuroprotection in PD by David K. Simon, MD, PhD

Targeting alpha synuclein in early Parkinson's disease. Clinical trials and future perspectives

Vitamin D and Fracture Risk among Adults | NEJM